Naghibzadeh, Nooshin
Salmani, Fatemeh
Nomiri, Samira
Tavakoli, Tahmine
Funding for this research was provided by:
This study was funded by ZistTakhmir pharmaceutical company, Tehran, Iran.
Article History
Received: 16 September 2021
Accepted: 28 February 2022
First Online: 7 March 2022
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. This study was approved by the Research Council and Ethics Committee of the Birjand University of Medical Sciences with the ethics code of IR.BUMS.REC.1398.305. It was also registered on the website of the Iranian registry of clinical trials (IRCT) with the following Number: IRCT20200106046021N1 on 14/01/2020 (ExternalRef removed). Informed written consent was obtained from all the patients. No costs were imposed on patients. The drugs used in the study, as well as the dose administered to patients, had no AEs or toxicity. The final report and analysis were performed without the names of the participants in the study.
: Not applicable.
: The authors declare that they have no competing interests.